SAREPTA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31)
SAREPTA THERAPEUTICS, INC. (SRPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) of $624.00 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-09.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue · last filed 2013-05-09
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $624.00K, a 67.87% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for the quarter ending 2012-12-31 was $555.00K, a 16.35% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for the quarter ending 2012-09-30 was $505.00K, a 2.43% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for the quarter ending 2012-06-30 was $747.00K.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2012 was $3.75M, a 35.00% increase from fiscal 2011.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2011 was $2.78M, a 4.16% increase from fiscal 2010.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2010 was $2.67M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|---|
| 2013-03-31 | $624.00K 10-Q · filed 2013-05-09 | $1.18M derived: sum of 2 quarters · filed 2013-05-09 | $1.68M derived: sum of 3 quarters · filed 2013-05-09 | $2.43M derived: sum of 4 quarters · filed 2013-05-09 | |
| 2012-12-31 | $555.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $1.06M derived: sum of 2 quarters · filed 2013-03-15 | $1.81M derived: sum of 3 quarters · filed 2013-03-15 | $3.75M 10-K · filed 2013-03-15 | |
| 2012-09-30 | $505.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $1.25M derived: sum of 2 quarters · filed 2012-11-07 | $3.19M 10-Q · filed 2012-11-07 | $3.67M derived: sum of 4 quarters · filed 2013-05-09 | |
| 2012-06-30 | $747.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $2.69M 10-Q · filed 2012-08-07 | $3.17M derived: sum of 3 quarters · filed 2013-05-09 | $3.66M derived: sum of 4 quarters · filed 2013-05-09 | |
| 2012-04-30 | $32.38K 10-Q · filed 2012-08-07 | ||||
| 2012-03-31 | $1.94M 10-Q · filed 2013-05-09 | $2.42M derived: sum of 2 quarters · filed 2013-05-09 | $2.91M derived: sum of 3 quarters · filed 2013-05-09 | ||
| 2011-12-31 | $477.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $970.00K derived: sum of 2 quarters · filed 2013-03-15 | $2.78M 10-K · filed 2013-03-15 | ||
| 2011-09-30 | $493.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $2.30M 10-Q · filed 2012-11-07 | |||
| 2011-06-30 | $1.81M 10-Q · filed 2012-08-07 | ||||
| 2010-12-31 | $2.67M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |